Drug intelligence / Profile preview

olanzapine + carbamazepine

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

**olanzapine + carbamazepine** is a combination of two small-molecule pharmaceutical drugs: olanzapine, an atypical antipsychotic, and carbamazepine, an anticonvulsant and mood stabilizer. This combination is sometimes used in the clinical management of manic or mixed episodes in bipolar disorder, typically when monotherapy is insufficient. Olanzapine acts chiefly as an antagonist at several neurotransmitter receptors including dopamine D2 and serotonin 5-HT2A, whereas carbamazepine stabilizes neuronal membranes by inhibiting voltage-gated sodium channels and also induces several cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. The pharmacokinetic interaction is significant: carbamazepine induces olanzapine metabolism, reducing olanzapine plasma concentrations, potentially lowering therapeutic efficacy. Combination therapy may have additive effects on mood stabilization but is associated with increased risk of weight gain and metabolic disturbances[1][2][3][5][6].

Other names
olanzapine plus carbamazepineolanzapine and carbamazepineolanzapine combinationcarbamazepine combination
02

Targets

UGT (UDP-glucuronosyltransferase family)CYP1A2 (Cytochrome P450 1A2)

Beyond the preview

Go deeper on olanzapine + carbamazepine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on olanzapine + carbamazepine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call